Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Merck KGaA
  6. News
  7. Summary
    MRK   DE0006599905

MERCK KGAA

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

DGAP-Adhoc : Merck KGaA raises forecast for full year 2021

05/04/2021 | 02:38pm EDT
DGAP-Ad-hoc: Merck KGaA / Key word(s): Forecast/Change in Forecast 
Merck KGaA raises forecast for full year 2021 
04-May-2021 / 20:36 CET/CEST 
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a 
service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Darmstadt, 4 May 2021. Based on high demand expected to continue throughout the year and a very strong first quarter of 
2021 with net sales of EUR 4.63 bn resulting in EBITDA pre^1 of EUR 1.51 bn and EPS pre^1 of EUR 2.18, Merck KGaA (the 
"Company") has raised its forecast for the entire group for fiscal 2021. The Company now projects net sales of approx. 
EUR 18.5 - 19.5 bn (previously "strong organic growth"). EBITDA pre^1 is anticipated to grow to approx. EUR 5.4 - 5.8 
bn for the group (previously "organic: high single-digit to low teens growth"). EPS pre^1 is projected to amount to 
approx. EUR 7.50 - 8.20. 
The Company will publish first-quarter 2021 figures as scheduled on 12 May 2021. 
^1 EBITDA pre and EPS pre are alternative performance measures not defined by international accounting standards, used 
by the Company to improve the comparability of business performance over time and within the industry. EBITDA pre means 
earnings before interest, income tax, depreciation and amortization as well as adjustments (Ergebnis vor Zinsen, 
Ertragsteuern, Abschreibungen und Anpassungen). EPS pre means profit after tax including adjustments per theoretical 
shares outstanding (see Merck Annual Report 2020). 
Contact: 
Andreas Cezanne, Head of Corporate Media Relations 
=---------------------------------------------------------------------------------------------------------------------- 
04-May-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and 
Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Merck KGaA 
              Frankfurter Str. 250 
              64293 Darmstadt 
              Germany 
Phone:        +49 (0)6151 72 - 2702 
E-mail:       Andreas.Cezanne@merckgroup.com 
Internet:     https://www.merckgroup.com/de 
ISIN:         DE0006599905 
WKN:          659990 
Indices:      DAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX 
EQS News ID:  1192510 
 
End of Announcement  DGAP News Service 
=------------ 

1192510 04-May-2021 CET/CEST

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1192510&application_name=news 
 

(END) Dow Jones Newswires

May 04, 2021 14:37 ET (18:37 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
DAX 1.34% 15399.65 Delayed Quote.12.25%
MERCK KGAA 1.03% 142.75 Delayed Quote.1.71%
All news about MERCK KGAA
05/07MERCK KGAA  : quaterly earnings release
05/07MERCK  : ALJ Bullock Grants-in-Part Motion For Summary Determination Of Violatio..
AQ
05/06MERCK KGAA  : Buy rating from Deutsche Bank
MD
05/05GLOBAL MARKETS LIVE : Lyft, Activision, General Electric...
05/05MERCK KGAA  : DZ Bank maintains a Buy rating
MD
05/05MERCK KGAA  : Warburg Research reaffirms its Neutral rating
MD
05/05MERCK KGAA  : UBS gives a Neutral rating
MD
05/05MERCK KGAA  : Sell rating from Goldman Sachs
MD
05/05MERCK KGAA  : JP Morgan keeps its Buy rating
MD
05/04Merck KGaA Raises 2021 Views After 'Very Strong' 1Q
DJ
More news
Financials
Sales 2021 18 591 M 22 610 M 22 610 M
Net income 2021 2 346 M 2 853 M 2 853 M
Net Debt 2021 9 074 M 11 036 M 11 036 M
P/E ratio 2021 26,0x
Yield 2021 1,04%
Capitalization 62 065 M 75 431 M 75 483 M
EV / Sales 2021 3,83x
EV / Sales 2022 3,52x
Nbr of Employees 58 127
Free-Float 29,7%
Chart MERCK KGAA
Duration : Period :
Merck KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK KGAA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 146,51 €
Last Close Price 142,75 €
Spread / Highest target 22,6%
Spread / Average Target 2,63%
Spread / Lowest Target -22,9%
EPS Revisions
Managers and Directors
NameTitle
Stefan Oschmann Chairman-Executive Board & CEO
Marcus Kuhnert Chief Financial Officer
Wolfgang Heinz Büchele Chairman-Supervisory Board
Nilesh Kumar Senior Investment Director
Christian Raabe Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
MERCK KGAA1.71%75 431
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD23.59%31 005
KYOWA KIRIN CO., LTD.19.05%16 579
SK BIOPHARMACEUTICALS CO., LTD.-36.09%7 602
BETTA PHARMACEUTICALS CO., LTD.-7.96%6 347
YUHAN CORPORATION-15.98%3 697